Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands |
Private Placement [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
|
Private Placement [Member]
Common Stock [Member]
|
Private Placement [Member]
Additional Paid-in Capital [Member]
|
Private Placement [Member]
AOCI Attributable to Parent [Member]
|
Private Placement [Member]
Noncontrolling Interest [Member]
|
Private Placement [Member] |
Preferred Stock [Member]
Series A Preferred Stock [Member]
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
AOCI Attributable to Parent [Member] |
Noncontrolling Interest [Member] |
Series A Preferred Stock [Member] |
Total |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance (in shares) at Dec. 31, 2020 | 0 | 53,551,126 | ||||||||||||||
| Balance at Dec. 31, 2020 | $ 0 | $ 26 | $ 201,598 | $ (157,392) | $ (471) | $ 43,761 | ||||||||||
| Issuance of common stock (in shares) | 3,790,755 | 9,808,418 | ||||||||||||||
| Issuance of common stock | $ 0 | $ 1 | $ 16,587 | $ 0 | $ 0 | $ 16,588 | ||||||||||
| Dividends from subsidiaries | $ 0 | $ 0 | 0 | 0 | (293) | (293) | ||||||||||
| December 2020 Public Offering warrants exercise (in shares) | 0 | 361,200 | ||||||||||||||
| December 2020 Public Offering warrants exercise | $ 0 | $ 0 | 903 | 0 | 0 | 903 | ||||||||||
| Beneficial conversion feature | 0 | 0 | 152 | 0 | 0 | $ 152 | 152 | |||||||||
| Acquisition of non-controlling interest | 0 | 0 | (341) | 0 | 341 | 0 | ||||||||||
| Net loss — the Company | 0 | 0 | 0 | (23,013) | 0 | (23,013) | ||||||||||
| Net loss — non-controlling interest | $ 0 | $ 0 | 0 | 0 | 872 | 872 | ||||||||||
| Options exercised (in shares) | 0 | 261,836 | ||||||||||||||
| Options exercised | $ 0 | $ 0 | 354 | 0 | 0 | 354 | ||||||||||
| Disposal of subsidiary | 0 | 0 | 0 | 0 | 204 | 204 | ||||||||||
| Stock-based compensation | $ 0 | $ 0 | 2,068 | 0 | 0 | 2,068 | ||||||||||
| Balance (in shares) at Dec. 31, 2021 | 3,790,755 | 63,982,580 | ||||||||||||||
| Balance at Dec. 31, 2021 | $ 0 | $ 27 | 221,321 | (180,405) | 653 | 41,596 | ||||||||||
| Issuance of common stock (in shares) | 3,185,000 | 1,750,000 | 0 | 7,585,529 | ||||||||||||
| Issuance of common stock | $ 0 | $ 0 | $ 6,518 | $ 0 | $ 0 | $ 6,518 | $ 0 | $ 1 | 2,203 | 0 | 0 | 2,204 | ||||
| Dividends from subsidiaries | 0 | 0 | 0 | 0 | (124) | (124) | ||||||||||
| Net loss — the Company | 0 | 0 | 0 | (43,700) | 0 | (43,700) | ||||||||||
| Net loss — non-controlling interest | $ 0 | $ 0 | 0 | 0 | 116 | $ 116 | ||||||||||
| Options exercised (in shares) | 0 | 16,464 | 16,464 | |||||||||||||
| Options exercised | $ 0 | $ 0 | [1] | 23 | 0 | 0 | $ 23 | |||||||||
| Stock-based compensation | $ 0 | $ 0 | 2,104 | 0 | 0 | 2,104 | ||||||||||
| Conversion of 2021 Private Placemat shares (in shares) | (3,790,755) | 3,790,755 | ||||||||||||||
| Conversion of 2021 Private Placemat shares | $ 0 | $ 1 | 0 | 0 | 0 | 1 | ||||||||||
| Balance (in shares) at Dec. 31, 2022 | 3,185,000 | 77,125,328 | ||||||||||||||
| Balance at Dec. 31, 2022 | $ 0 | $ 29 | $ 232,169 | $ (224,105) | $ 645 | $ 8,738 | ||||||||||
| ||||||||||||||||
| X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase in noncontrolling interest from a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares issued which are neither cancelled nor held in the treasury. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The gross value of stock issued during the period upon the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A convertible instrument contains a BCF when the conversion price is less than the fair value of the shares into which the instrument is convertible at the commitment date. The conversion option related to the Series A convertible preferred shares has intrinsic value at the issuance date and will therefore be recorded as a beneficial conversion feature. A BCF would be separated from a convertible instrument and recorded in additional paid-in capital. No definition available.
|
| X | ||||||||||
- Definition The number of shares issued during the period for warrants exercised. No definition available.
|
| X | ||||||||||
- Definition Value of stock issued during the period for warrants exercised. No definition available.
|